Circio Holding ASA has established technical in vivo proof of concept for its proprietary Circvec circular RNA platform by demonstrating statistically significant improvement in durability over mRNA-based expression.

Researchers from the U.K.’s University of Birmingham have filed for protection of an implantable device for targeted drug delivery in patients who have undergone surgery, particularly surgery to remove one or more tumors.

Eli Lilly and Co. continues its development of an oral drug delivery device that can successfully deliver a drug that would otherwise be ineffective when taken orally.

Vernalis (R&D) Ltd., a subsidiary of Hitgen Inc., and C4x Discovery Holdings plc have entered into a collaboration to identify modulators of an undisclosed, hard-to-drug, high-value target involved in inflammatory disease.

Odyssey Therapeutics Inc. has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small-molecule medicines against select therapeutic targets.

A group of scientists at Shanghai Virogin Biotech Co. and Zhujiang Hospital in China designed a new mRNA vaccine that could prevent tumor formation associated with human papillomavirus 16 (HPV16) and also reduce its size if used as a treatment.

Altamira Therapeutics Ltd. has entered into a collaboration agreement with Univercells SA to evaluate the use of the company’s proprietary Semaphore platform for the delivery of mRNA vaccines.

Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with the University of Oxford to verify drug discovery seeds and obtain screening compounds for the creation of new medicines.

Deep learning algorithms have enabled the discovery of molecular structures of interest in biomedicine to design treatments against aggressive diseases such as idiopathic pulmonary fibrosis (IPF). Scientists at Insilico Medicine Inc. selected a target for IPF using artificial intelligence (AI), then designed an inhibitor to block it, and tested it in vitro, in vivo, and in clinical trials.

Samsung Life Science Fund, created jointly between Samsung Biologics Co. Ltd., Samsung Bioepis Co. Ltd. and Samsung C&T, and managed by Samsung Venture Investment Corp., and Brickbio Inc. have announced Samsung’s investment in preclinical-stage biopharmaceutical company Brickbio.